Insight into Autophagy in Platinum Resistance of Cancer

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2023 Jan 27

PMID 36705869

Authors

Fang Yang

Ke Xu

Yan-Gang Zhou

Tao Ren

Affiliations

Soon will be listed here.

Abstract

Platinum drugs, as a class of widely used chemotherapy agents, frequently appear in the treatment of cancer at different phrases. However, platinum resistance is the major bottleneck of platinum drugs for exerting anti-tumor effect. At present, the mechanism of platinum resistance has been thoroughly explored in terms of drug delivery methods, DNA damage repair function, etc., but it has not yet been translated into an effective weapon for reversing platinum resistance. Recently, autophagy has been proved to be closely related to platinum resistance, and the involved molecular mechanism may provide a new perspective on platinum resistance. The aim of this review is to sort out the studies related to autophagy and platinum resistance, and to focus on summarizing the relevant molecular mechanisms, so as to provide clues for future studies related to autophagy and platinum resistance.

Citing Articles

Combining Copper and Zinc into a Biosensor for Anti-Chemoresistance and Achieving Osteosarcoma Therapeutic Efficacy.

Lim Y, Zaidi A, Miskon A Molecules. 2023; 28(7).

PMID: 37049685 PMC: 10096333. DOI: 10.3390/molecules28072920.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

Chen F, Luo H, Xing L, Liang N, Xie J, Zhang J . Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers. Thorac Cancer. 2017; 9(1):59-65. PMC: 5754287. DOI: 10.1111/1759-7714.12536. View

Meng X, Liao Y, Liu X, Li S, Shi M, Zeng X . Concurrent cisplatin-based chemoradiotherapy versus exclusive radiotherapy in high-risk cervical cancer: a meta-analysis. Onco Targets Ther. 2016; 9:1875-88. PMC: 4821385. DOI: 10.2147/OTT.S97436. View

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Rosenberg B, VANCAMP L, Trosko J, Mansour V . Platinum compounds: a new class of potent antitumour agents. Nature. 1969; 222(5191):385-6. DOI: 10.1038/222385a0. View

Jalal S, Earley J, Turchi J . DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res. 2011; 17(22):6973-84. PMC: 3218201. DOI: 10.1158/1078-0432.CCR-11-0761. View

10.

Bonanno L, Favaretto A, Rosell R . Platinum drugs and DNA repair mechanisms in lung cancer. Anticancer Res. 2014; 34(1):493-501. View

11.

Dasari S, Tchounwou P . Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364-78. PMC: 4146684. DOI: 10.1016/j.ejphar.2014.07.025. View

12.

Lord C, Ashworth A . The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-94. DOI: 10.1038/nature10760. View

13.

Achkar I, Abdulrahman N, Al-Sulaiti H, Joseph J, Uddin S, Mraiche F . Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. J Transl Med. 2018; 16(1):96. PMC: 5896132. DOI: 10.1186/s12967-018-1471-1. View

14.

Levine B, Kroemer G . Biological Functions of Autophagy Genes: A Disease Perspective. Cell. 2019; 176(1-2):11-42. PMC: 6347410. DOI: 10.1016/j.cell.2018.09.048. View

15.

Yang Y, Klionsky D . Autophagy and disease: unanswered questions. Cell Death Differ. 2020; 27(3):858-871. PMC: 7206137. DOI: 10.1038/s41418-019-0480-9. View

16.

Ma B, Cao W, Li W, Gao C, Qi Z, Zhao Y . Dapper1 promotes autophagy by enhancing the Beclin1-Vps34-Atg14L complex formation. Cell Res. 2014; 24(8):912-24. PMC: 4123296. DOI: 10.1038/cr.2014.84. View

17.

Hu Y, Jahangiri A, Delay M, Aghi M . Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res. 2012; 72(17):4294-9. PMC: 3432684. DOI: 10.1158/0008-5472.CAN-12-1076. View

18.

Buchser W, Laskow T, Pavlik P, Lin H, Lotze M . Cell-mediated autophagy promotes cancer cell survival. Cancer Res. 2012; 72(12):2970-9. PMC: 3505669. DOI: 10.1158/0008-5472.CAN-11-3396. View

19.

Baehrecke E . Autophagy: dual roles in life and death?. Nat Rev Mol Cell Biol. 2005; 6(6):505-10. DOI: 10.1038/nrm1666. View

20.

Mathew R, Karantza-Wadsworth V, White E . Role of autophagy in cancer. Nat Rev Cancer. 2007; 7(12):961-7. PMC: 2866167. DOI: 10.1038/nrc2254. View